Published

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: European psychiatry: the journal of the Association of European Psychiatrists
Date: 2023-07-19
Source: Europe PMC
DOI: Unavailable
PubMed: Unavailable

Authors

Goodwin G Marwood L Mistry S Nowakowska A Simmons H Tsai J Williams S Young M Malievskaia E.

Watch author

Derived topics and classifications

psilocybin Depression Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03 Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.Frontiers in psychology · 2025-01-01 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Comparative Efficacy of Hallucinogens in Treating Mood Disorders Through a Meta-Analysis of Symptom Reduction, Dosage, and DurationJournal of International Crisis and Risk Communication Research · 2024-12-31 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-13 Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30 The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01 The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01